Gossamer bio announces clinical trial collaboration agreement with merck

Gossamer bio announces clinical trial collaboration agreement with merck to evaluate gb1275 in combination with keytruda® (pembrolizumab) in selected advanced solid tumors.gossamer bio inc - phase 1/2 trial ongoing with multiple patients dosed in gb1275 monotherapy dose escalation.gossamer bio inc - phase 2 consists of expansion cohorts evaluating gb1275 in combination with keytruda or chemotherapy.gossamer bio inc - expects to report initial data from phase 1 portion of study in h2 of 2020.gossamer bio inc - phase 1 consisting of dose escalation of three gb1275 regimens including one with keytruda.
GOSS Ratings Summary
GOSS Quant Ranking